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ABSTRACT
The glucocorticoid-induced TNFR family-related protein (GITR) and its ligand play 
a critical role in the pathogenesis of autoimmune arthritis by enhancing the Th17 cell 
response, but their molecular mechanisms remain largely unclear. This study aims to 
define the role of p38 mitogen-activated protein kinases (MAPK) and signal transducer 
and activator of transcription 3 (STAT3) signaling in GITRL-induced Th17 cells in 
autoimmune arthritis. We found that the p38 phosphorylation was enhanced by GITRL 
in activated CD4+T cells, and the p38 inhibitor restrained the GITRL-induced Th17 
cell expansion in a dose-dependent manner. Moreover, there was decreased STAT3 
activity on Tyr705 and Ser727 with the p38 inhibitor in vitro. Notably, the p38 inhibitor 
could prevent GITRL-treated arthritis progression and markedly decrease the Th17 
cell percentages. The phosphorylation of the Tyr705 site was significantly lower in the 
GITRL-treated CIA mice administrated with the p38 inhibitor. A significantly higher 
phosphorylation of p38 was detected in RA patients and had a positive relationship 
with the serum level of anti-cyclic citrullinated peptide (anti-CCP) antibody. Our 
findings have indicated that GITRL could promote Th17 cell differentiation by p38 
MAPK and STAT3 signaling in autoimmune arthritis.
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease 
characterized by chronic inflammation of synovial joints 
and the progressive destruction of cartilage and bone 
tissue, ultimately leading to disability [1]. Th17 cells, a 
subset of helper T cell populations that selectively produce 
IL-17, have developed a reputation as a critical element 
in RA patients [2, 3] and collagen-induced arthritis (CIA) 
mice [4]. Accumulated data have shown that TGF-β 
with IL-6 and IL-23 instruct Th17 cell differentiation 
via RORγt and STAT3 [5, 6], and IL-21 is needed for 
the expansion of Th17 cells in autocrine signaling [7]. 
Furthermore, STAT3 is a vital transcription factor for Th17 
cell differentiation by directly binding and regulating Il17a 
and the Il21 locus, as well as regulating RORγt expression 
[8, 9]. 
The murine glucocorticoid-induced tumor necrosis 
factor receptor-related protein (GITR) had been described 
in 1997 as a dexamethasone-inducible molecule in T cells 
[10]. A low level of GITR is constitutively expressed 
on effector T cells and increases upon activation [11]. 
However, regulatory T cells (Treg) constitutively express 
high levels of GITR, and GITR ligand (GITRL) can 
abrogate the suppressive function [12, 13]. GITRL is 
expressed on antigen-presenting cells (APCs), such as 
DCs, macrophages, and B cells [14, 15]. A recent study 
demonstrated a marked expansion of Th17 cells when 
induced from naïve CD4+T cells cultured with GITRL 
protein. Moreover, an administration of recombinant 
GITRL in CIA mice enhanced Th17 cell generation and 
exacerbated arthritis development [16]. However, the 
molecular mechanisms underlying GITRL modulation of 
Th17 cells remain largely unclear. Current studies have 
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shown GITR cross-linking provided costimulation of naïve 
and activated T cells and resulted in activation of MAPKs 
[17, 18]. P38 MAPK is a member of MAPK family, and 
activation of p38 MAPK signaling in CD4+T cells plays 
a pivotal role in Th17 cell function by regulating IL-17 
production [19-21]. 
In this study, we firstly found that the cross-linking 
of GITR triggered by GITRL provided an enhanced 
phosphorylation of p38 MAPK and further induced the 
phosphorylation of STAT3 in activated CD4+T cells. We 
also demonstrated that Th17 cell differentiation induced 
by GITRL protein could be suppressed after culturing 
Th17 cells with a p38 MAPK inhibitor. Moreover, 
the promotion of arthritis by mGITRL in collagen-
immunized mice could be relieved by administering a 
p38 MAPK inhibitor. Furthermore, elevated levels of 
p38 MAPK phosphorylation were detected in CD4+T 
cells from the peripheral blood of RA patients, which 
displayed a significant correlation with increased serum 
levels of anti-CCP antibody in these patients. Thus, these 
results have revealed an important pathway for Th17 
cell differentiation induced by GITRL and a previously 
unappreciated role of p38 MAPK in the pathogenesis of 
autoimmune arthritis.
RESULTS
P38 MAPK is necessary for GITRL-induced Th17 
differentiation
To characterize p38 MAPK signaling pathways that 
may contribute to GITRL-induced cellular effects, we 
analyzed the phosphorylation of p38 MAPK in activated 
T cells using different concentrations of GITRL protein. 
When stimulated with 0.5 or 1.0 µg/ml GITRL protein, 
the activated CD4+T cells had higher phosphorylation 
of p38 MAPK (Figure 1A). After that, we analyzed the 
phosphorylation of p38 MAPK in CD4+T cells using 
GITRL protein (1.0 µg/ml) for 10, 20, 40, and 60 min. The 
results show that the phosphorylation of p38 was enhanced 
when stimulated with 1.0 µg/ml GITRL protein for 10 or 
20 min (Figure 1B). 
Next, we investigated if p38 MAPK had an effect on 
GITRL-induced Th17 cell differentiation. Naïve CD4+T 
cells were induced with anti-CD3 mAb and GITRL protein 
under Th17 differentiation conditions in the presence of 
varying concentrations of the p38 MAPK inhibitor (0, 
2.5, 5, 7.5, and 10 µM). There was a clear decrease of the 
proportion of Th17 cells in the presence of the p38 MAPK 
inhibitor (Figure 1C).Compared with the supernatant 
from developing Th17 cells induced by GITRL, IL-17 
concentration was significantly reduced in the presence 
of p38 MAPK inhibitor (Figure 1D). Additionally, Th17 
cells frequency, IL-17 concentration and associated factors 
of mRNA expression were decreased in a dose-dependent 
manner by the p38 MAPK inhibitor during the GITRL-
induced Th17 cell differentiation (Figure 1E-1H). These 
results indicated that p38 MAPK is necessary for GITRL-
induced Th17 cell differentiation. 
GITRL promotes the phosphorylation of STAT3 
on Tyr705 and Ser727 via p38 MAPK in Th17 cell 
differentiation
The classical JAK-STAT3 signaling pathway 
and Tyr705 phosphorylation are characteristic of 
STAT3 activation and a requisite condition of Th17 cell 
differentiation. Apart from the Tyr705 site, Ser727 is 
another important phosphorylation site of STAT3[23-25]. 
Previous studies have found p38 MAPK could promote 
the phosphorylation of STAT3 on Ser727 [26, 27]. 
After treatment with 0.5 or 1.0 μg/mL GITRL 
protein, the phosphorylation of STAT3 Tyr705 and 
Ser727 increased in the activated CD4+T cells (Figure 
2A). Additionally, the phosphorylation level of STAT3 
Tyr705 was accelerated with GITRL protein after 20 or 
40 min. The phosphorylation level of the Ser727 site 
was higher after a 10 or 20 min incubation with GITRL 
protein (Figure 2B). To explore if p38 MAPK modulates 
the phosphorylation of STAT3, activated CD4+T cells were 
pretreated with the p38 MAPK inhibitor and treated with 
GITRL for 20 min. There was decreased activity of STAT3 
on Tyr705 and Ser727 with pretreatment of the p38 MAPK 
inhibitor (Figure 2C). These data show that GITRL protein 
promotes the phosphorylation of STAT3 via p38 MAPK.
To study the function of STAT3 during GITRL-
induced Th17 cell differentiation, we observed the 
expansion of Th17 cells in the presence or absence of a 
STAT3 inhibitor. Compared with the supernatant from 
the developing Th17 cells induced by GITRL, IL-17 
production was significantly reduced in the presence 
of the STAT3 inhibitor (Figure 2D). The proportion of 
Th17 cells was also decreased by the STAT3 inhibitor 
in this condition (Figure 2E). Next, we found that the 
concentration of IL-21 and relative expression of IL-21 
mRNA reached its peak after incubating with GITRL for 
72 hours (Figure 2F, 2G). Notably, the increase in IL-
21 production and IL-21 mRNA expression by GITRL 
protein could be decreased with the STAT3 inhibitor 
(Figure 2H, 2I).
Therefore, it may be inferred that GITRL protein 
facilitated the activation of STAT3 on Tyr705 and Ser727 
via p38 MAPK and further induce Th17 differentiation in 
vitro. 
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Figure 1: p38 MAPK is necessary for GITRL-induced Th17 differentiation. A. Naïve CD4+T cells were activated by an 
anti-CD3 mAb (1 μg/mL) and GITRL protein (1 μg/mL) for 72 hours. The activated cells were washed and restimulated with different 
concentrations of GITRL protein (0, 0.5, 1.0, 2.0 μg/mL) at 37 °C for 20 min. The phosphorylation of p38 MAPK was detected by Western 
blot. B. Naïve CD4+T cells were activated by anti-CD3 mAb (1 μg/mL) and GITRL protein (1 μg/mL) for 72 hours. The activated cells 
were washed and restimulated with GITRL protein (1 μg/mL) at 37 °C for 10-60 min. The phosphorylation of p38 MAPK was detected 
by Western blot. C., D. Naïve CD4+T cells were cultured with TGF-β (2.5 ng/mL), IL-6 (30 ng/mL), IL-23 (30 ng/mL), anti-IFN-γ (5 μg/
mL), anti-IL-4 (5 μg/mL) and GITRL protein (1 μg/mL) in a 24-well plate precoated with anti-CD3 mAb (1 μg/mL) for 72 hours in the 
presence or absence of the p38 MAPK inhibitor SB203580 (5 μM); the DMSO was the solvent of SB203580. The frequencies of Th17 
cells in cultures with different treatments were analyzed by FCM C. The concentration of IL-17 in the culture supernatant was detected by 
ELISA D., E., F., G., H. Naïve CD4+T cells were cultured under Th17 cell differentiation conditions and treated with GITRL protein (1 
μg/mL) for 72 hours in the presence of SB203580 (0, 2.5, 5, 10 μM) or the solvent control. The frequencies of Th17 cells in cultures with 
different treatments were analyzed by FCM E.. The concentrations of IL-17 in the culture supernatant was detected by ELISA F.; relative 
expression of IL-17 G. and RORγt H. mRNA were detected by qRT-PCR. Data are mean±SD. ***, P < 0.001. 
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Figure 2: GITRL protein promotes the phosphorylation of STAT3 on Tyr705 and Ser727 via p38 MAPK in Th17 cell 
differentiation. A. Purified Naïve CD4+T cells were activated by anti-CD3 mAb (1 μg/mL) and GITRL protein (1 μg/mL) for 72 hours. 
The activated cells were washed and restimulated with different concentrations of GITRL protein at 37 °C for 20 min. The phosphorylation 
of STAT3 Tyr705 and Ser727 was detected by Western blot.B. The activated CD4+T cells were restimulated with GITRL protein (1 μg/mL) 
at 37 °C for different lengths of time. The phosphorylation of STAT3 Tyr705 and Ser727 was detected by Western blot.C. The activated 
CD4+T cells were pretreated with SB203580 (5 μM) for 30, 60, 90, and 120 min and restimulated with GITRL protein (1 μg/mL) for 20 min 
at 37 °C. The phosphorylation of STAT3 Tyr705 and Ser727 was detected by Western blot.D., E. Naïve CD4+T cells were cultured under 
Th17 condition as previously described and treated with GITRL protein (1 μg/mL) for 72 hours in the presence or absence of the STAT3 
inhibitor Stattic (20 μM). DMSO was used as the solvent of Stattic. The concentration of IL-17 in the culture supernatant was detected 
by ELISA D.. The frequencies of Th17 cells in the cultures with the different treatments were analyzed by FCM E., F., G. Naïve CD4+ T 
cells were cultured in the condition as previously described with either GITRL protein (1 μg/mL) or control protein for 72 hours. IL-21 
production F. and IL-21 mRNA expression G. was detected by ELISA and qRT-PCR, respectively, every 24 hours.H., I. Naïve CD4+ T 
cells were cultured in the conditions previously described and treated with either GITRL protein (1 μg/mL) or a control protein for 72 hours 
in the presence or absence of Stattic (20 μM). DMSO was the solvent of Stattic. IL-21 production H. and IL-21 mRNA expression I. was 
detected by ELISA and qRT-PCR, respectively. Data are mean±SD. *, P < 0.05; ***, P < 0.001.
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P38 MAPK inhibitor alleviates arthritis 
progression in GITRL-treated CIA mice
To define the function of p38 MAPK in GITRL-
treated CIA mice, the mice were divided into groups. 
The scheme of CIA induction and treatment is depicted 
in Figureure 3A. In the CIA-GITRL-SB203580 group, 
arthritis symptoms were alleviated by the p38 MAPK 
Figure 3: P38 MAPK inhibitor alleviates arthritis progression in the GITRL-treated CIA mice. A. The scheme of CIA 
induction, GITRL protein and SB203580 administration. The DBA/1J mice were immunized with CII/CFA on day 0 and boosted with CII/
IFA on day 21. The CIA-GITRL group was intravenously injected with GITRL protein (20 μg per mouse) daily for 5 consecutive days 
(from day 22 to day 26). In addition to being injected with GITRL protein, the CIA-GITRL-SB203580 and CIA-GITRL-Carrier group 
received 2.5 mg/kg/d SB203580 by ip injection in a total volume of 200 μL or an equal volume of carrier every day from the 20th day after 
first immunization. The mice were sacrificed on day 42 for various experiments (n = 6 for each group). B. Photographs of the hind ankle 
of the mice receiving the different treatments. C. The incidence of arthritis development of the immunized mice treated with GITRL (CIA-
GITRL), GITRL and SB203580 (CIA-GITRL -SB203580), or GITRL and Carrier (CIA-GITRL-Carrier) was monitored every 2 days.D. 
The clinical scores of arthritis severity were assessed in the CIA-GITRL, CIA-GITRL -SB203580 and CIA-GITRL-Carrier groups. E. The 
inflamed joints were sectioned for hematoxylin and eosin staining. Representative sections of joint tissue from each treatment group are 
shown (original magnification,×400).
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Figure 4: The p38 MAPK inhibitor reduced the Th17 cell response in the GITRL-treated CIA mice. A. The frequency of 
Th17 cells in spleens from CIA mice with different treatments was analyzed by flow cytometry. The percentages of Th17 cells are indicated 
in representative dot plots.B. The total number (left) or percentages (right) of Th17 cells in spleens from three treatment groups are shown. 
C. The frequency of Th17 cells in draining lymph nodes from CIA mice with different treatments was analyzed by flow cytometry; 
percentages of Th17 cells are indicated in representative dot plots.D. The total number (left) and percentages (right) of Th17 cells in lymph 
nodes from three treatment groups were shown. E. The phosphorylation level of STAT3 Tyr705 and Ser727 in the spleen CD4+T cells of the 
mice from the different groups was detected by Western blot. The results indicated are in a representative photo.F., G. The phosphorylation 
level of STAT3 Tyr705 F. and Ser727 G. in the spleen CD4+T cells of the mice from the different groups. Data are mean±SD. *, P < 0.05.
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inhibitor. Changes included later onset of arthritis, reduced 
symptoms, and decreased clinical scores and incidence 
of disease (Figure 3B-3D). Moreover, histopathological 
analysis revealed less pronounced synovial inflammation, 
cartilage damage, and bone erosion in the joint tissues of 
mice in the CIA-GITRL-SB203580 group (Figure 3E). 
Next, the number and frequency of Th17 cells were 
examined in the spleens and draining lymph nodes of 
the three groups of CIA mice. The percentage of Th17 
cells in the spleens were significantly decreased in mice 
from the CIA-GITRL-SB203580 group compared with 
the CIA-GITRL group. The reduction of total number of 
Th17 cells in the CIA-GITRL-SB203580 group was non-
significant, but it has a slight trend toward significance (p 
= 0.115) (Figure 4A, 4B). The total number and frequency 
of Th17 cells in the draining lymph nodes were markedly 
decreased in the CIA-GITRL-SB203580 group compared 
with the CIA-GITRL group (Figure 4C, 4D). In addition, 
the CD4+T cells from the spleens of the CIA mice were 
detected by the phosphorylation of STAT3 on Tyr705 
and Ser727 sites with a Western blot. The CIA-GITRL-
SB203580 group had a significantly lower phosphorylation 
level of STAT3 on the Tyr705 site in their CD4+T cells 
from the spleens, but the phosphorylation level of STAT3 
on the Ser727 site has no difference (p = 0.206) (Figure 
4E-4G). These results suggest that p38 MAPK inhibitor 
may inhibit arthritis progression and reduce Th17 cells in 
GITRL-treated CIA mice.
The p38 MAPK phosphorylation is upregulated in 
CD4+T cells from RA patients
Previously, we found that serum GITRL is 
significantly increased in and is positively correlated with 
serum IL-17A in RA patients. Therefore, we investigated 
the expression of the p38 MAPK in CD4+T cells and 
analyzed the percentage of Th17 cells from the peripheral 
blood of RA patients. Remarkably, the phosphorylation 
of p38 MAPK in the CD4+T cells and the percentage of 
Th17 cells from RA patients was significantly higher than 
the cells isolated from the healthy controls (Figure 5A, 
5B). Furthermore, we analyzed the correlation between the 
serum level of anti-CCP antibody and phosphorylation of 
p38 MAPK in the CD4+T cells from RA patients. There 
was a positive correlation between these two parameters 
(r = 0.5545, p = 0.0169) (Figure 5C). 
DISCUSSION
GITR-GITRL cross-linking costimulated naïve 
and activated T cells and resulted in MAPK activation. 
The MAPK family includes three main members: p38 
MAPK, extracellular signal-regulated kinase (ERK) and 
c-Jun N-terminal kinase (JNK). The individual MAPKs 
are activated by different stimuli and are implicated 
in developing immune responses. Studies have shown 
the p38 MAPK signaling pathway is essential for IL-
17 production in CD4+T cells, and the regulation of p38 
MAPK activity in vivo could influence the process and 
severity of EAE [19-21]. On the contrary, several studies 
have certified a negative function of ERK signaling during 
the generation of Th17 cells. Inhibition of ERK signaling 
enhanced the generation of Th17 cells in vitro and 
increased pathogenic potency in vivo [28]. Additionally, 
researchers have found that JNK plays a dual function 
in Th17 cell development. JNK inhibition dramatically 
enhanced IL-17 and CCR6 expression in developing Th17 
cells, indicating that the JNK pathway controls Th17 cell 
differentiation. Over-expression of JNK enhanced Rorc 
Figure 5: P38 MAPK phosphorylation was upregulated in the CD4+T cells from RA patients. A. PBMCs from 15 healthy 
controls and 18 patients were stained for phospho-p38 MAPK. The mean fluorescence intensity (MFI) of phosphor-p38 MAPK in CD4+T 
cells was compared between the RA patients and the healthy controls. All the values were gated on the CD3+CD4+ T cells.B. PBMCs from 
15 healthy controls and 18 patients were stimulated for 5 hours with PMA/ionomycin and then stained for the cell surface molecule CD3 
and CD8 as well as intracellular IL-17 and analyzed by flow cytometry. Percentages of Th17 cells were compared between RA patients and 
healthy controls.C. The correlation between the MFI of phospho-p38 MAPK in CD4+T cells and serum level of anti-CCP antibody in RA 
patients (r = 0.5545, p = 0.0169). Each data point represents an individual subject. *, P < 0.05; **, P < 0.01.
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expression in the absence of TGF-β (Th0+IL-6) in primary 
T cells [19]. Nevertheless, the involvement of p38 MAPK 
in GITRL induced Th17 cell differentiation has not been 
described. Our data showed that GITRL could enhance 
the phosphorylation of p38 in CD4+T cells. Meanwhile, 
treatment of p38 MAPK inhibitor restrains GITRL-
induced Th17 cell expansion in a dose-dependent manner. 
Thus, p38 MAPK activity plays an important role in the 
regulation of Th17 cell differentiation induced by GITRL 
protein in vitro. Recently, a study has evaluate p38 MAPK 
deficiency in CIA model and found that p38γ/δ regulates 
the arthritis in CIA mice via altered T cell responses to 
CII and the level of IL-17 in mouse paws [29]. These 
results suggest an important role of p38 MAPK during the 
process of CIA. According to our results, we inferred the 
alteration of p38 MAPK activity may influence GITRL 
protein-induced arthritis in vivo. To define the function 
of p38 MAPK during GITRL protein-induced arthritis in 
vivo, a p38 MAPK inhibitor or control was administered to 
GITRL-treated CIA mice. Interestingly, the administration 
of the p38 MAPK inhibitor could prevent GITRL-treated 
arthritis progression, including decreasing clinical scores 
and incidence of CIA. Importantly, the increase of 
Th17 cells in GITRL-treated CIA mice was reduced by 
administration of the p38 MAPK inhibitor. Thus, these 
findings reveal a critical role for P38 MAPK in driving the 
development of Th17 cells in GITRL-treated CIA mice.
In patients with RA, Th17 cells and IL-17 drive 
both inflammation and joint damage. The elevated 
serum level of GITRL is positively correlated with 
serum concentration of IL-17 [16]. Consistent with the 
function of p38 MAPK activity in GITRL-induced Th17 
cell differentiation in vitro and arthritis pathogenesis in 
CIA, a significantly higher phosphorylation level of p38 
MAPK was detected in the peripheral CD4+T cells from 
the RA patients than in those from the healthy control 
subjects. There was a positive relationship between the 
serum level of anti-CCP antibody and the p38 MAPK 
phosphorylation in CD4+T cells from the RA patients. 
These results suggest that the enhancement of p38 MAPK 
phosphorylation and the increase in Th17 cells may be 
involved in RA pathogenesis. However, whether p38 
MAPK phosphorylation in CD4+T cells could serve as a 
biomarker for disease activity remains to be investigated. 
What is the downstream signaling of GITRL-
mediated activation of p38 MAPK in Th17 cells? 
Recently, phosphorylation at the Ser727 site of STAT3 
by all three MAPK family members has been reported 
in response to different extracellular stimuli, suggesting 
a cross-talk between MAPK cascades and JAK-STAT 
pathways [26, 27, 29]. Importantly, STAT3 is a key 
transcription factor for Th17 differentiation. Full 
activation of STAT3 requires dual phosphorylation of 
Tyr705 and Ser727 sites [23, 30, 31]. Interestingly, the 
phosphorylation of STAT3 in activated CD4+T cells at 
Tyr705 and Ser727 was enhanced after the treatment with 
GITRL protein, and the enhancement of phosphorylation 
of STAT3 by GITRL was reversed once treated with the 
p38 MAPK inhibitor. Meanwhile, Th17 cell expansion and 
IL-21 production induced by GITRL could be restrained 
by the STAT3 inhibitor. Additionally, our results showed 
that GITRL could reinforce the phosphorylation of STAT3 
on both Tyr705 and Ser727 via promoting p38 MAPK 
activity in vitro. The treatment of the p38 MAPK inhibitor 
in the GITRL-treated CIA mice markedly decreased the 
phosphorylation of STAT3 on Tyr705 in CD4+T cells, but 
the decrease at the Ser727 site was small. Additionally, 
the role of GITRL-mediated activation of p38 MAPK in 
directly contributing to phosphorylation of STAT3 in Th17 
cells remains to be clarified. 
Taken together, these results indicate that GITRL 
could promote Th17 cell differentiation by p38 MAPK 
and STAT3 signaling in autoimmune arthritis, which 
is considered a central pathogenesis of autoimmune 
disorders. 
MATERIALS AND METHODS
Mice
DBA/1J mice (6- to 8-week-old, male) were 
purchased from the Shanghai Slac Laboratory Animal 
Company (Shanghai, China) and maintained in a specific 
pathogen-free animal facility at Jiangsu University. All the 
animal experimental procedures used in this study were 
approved by the Jiangsu University Animal Ethics and 
Experimentation Committee.
Patients
Eighteen patients with RA ranging from 31 to 84 
years old (52.56 ± 17.32, data correspond to the arithmetic 
mean±SD) were included in this study. All the patients 
met the American College of Rheumatology (ACR) 1987 
and The European League against Rheumatism (EULAR) 
2009 revised criteria for the classification of RA. Fifteen 
healthy subjects free of rheumatic disease, chronic pain, 
cardiovascular complaints, or other chronic inflammatory 
diseases were the control. The peripheral blood was taken 
from patients and healthy subjects after fasting for 8 hours 
in the morning. The serum concentration of the anti-CCP 
antibody was measured using a standard ELISA and 
ELISA reader (Bio-Rad). Peripheral blood mononuclear 
cells (PBMCs) were prepared from all the patients and the 
healthy controls for the subsequent measurements.
All samples were taken in accordance with 
regulations and with the approval of the Affiliated People’s 
Hospital of Jiangsu University.
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Cell culture
CD4+ naïve T cells were purified from mice spleen 
cell suspensions by magnetic beads using a CD4+CD62L+T 
Cell Isolation Kit II (Miltenyl Biotec, DE). Naïve CD4+T 
cells were activated using 1 μg/mL anti-CD3 mAb 
(Biolegend) and 1 μg/mL GITRL protein for 72 hours. 
The activated cells were washed and restimulated with 
GITRL protein at 37 °C. The activated CD4+T cells 
were pretreated with 5 μM of the p38 MAPK inhibitor 
SB203580 (Cell Signaling Technology, CST) for 30, 60, 
90, and 120 min and restimulated with GITRL protein 
for 20 min. Cultured cells were prepared for Western blot 
analysis. Recombinant GITRL protein was produced and 
purified as previously described [16].
For Th17 cell differentiation, naïve CD4+T cells 
were cultured in the presence of 2.5 ng/ml TGF-β 
(PeproTech), 30 ng/ml IL-6 (PeproTech), 30 ng/ml IL-23 
(PeproTech), 5 μg/ml anti-IFN-γ (Biolegend) and 5 μg/ml 
anti-IL-4 (Biolegend) in a 24-well plate precoated with 
anti-CD3 mAb (1 μg/mL) and treated with either GITRL 
protein or control protein for 72 hours in the presence or 
absence of SB203580. 
Induction and evaluation of collagen-induced 
arthritis (CIA)
Briefly, 100 μL (1 mg/mL) of bovine type II 
collagen (CII; Chondrex) was emulsified with an equal 
volume of complete Freund’s adjuvant (CFA, 2 mg/mL; 
Chondrex) and administered intradermally at the base of 
tail into DBA/1J mice. On day 21, a booster emulsion 
prepared with CII and incomplete Freund’s adjuvant was 
intradermally administered near the primary injection site. 
Mice received 2.5 mg/kg/d SB203580 by IP injection in 
a total volume of 200 μL or an equal volume of carrier 
every day from the 20th day after the first immunization. 
Beginning on day 21, the mice were scored for arthritis 
severity every two days as previously described [22]. 
Eighteen mice were randomly and equally separated into 
three groups. The first group was treated with the mGITRL 
protein (CIA-GITRL group), the second group with 
mGITRL and the p38 inhibitor SB203580 (CIA-GITRL-
SB203580 group), and the last group with mGITRL and 
the p38 inhibitor solvent (CIA-GITRL-Carrier group).
Western blot analysis
Whole-cell lysates were prepared using 1-5×106 
cells in RIPA lysis buffer, separated by SDS-PAGE, 
and transferred to PVDF membranes. Primary Abs used 
for Western blot analysis included anti-phospho-p38 
MAPK (CST), anti-phospho-STAT3 (Tyr705; CST), 
anti-phospho-STAT3 (Ser727; CST), anti-STAT3 (Santa 
Cruz), and anti-actin (Abcam). Anti-rabbit-HRP and anti-
mouse-HRP (Jackson ImmunoResearch Laboratories) 
were used as secondary Abs. The bands were detected 
by chemiluminescent detection (Champion Chemical) 
according to the manufacturer’s instructions.
Reverse transcription and real-time PCR
Total RNA was extracted from splenocytes 
from the mice or from cultured CD4+T cells using 
TRIzol (Invitrogen). The RNA was subjected to 
reverse transcription, and was performed as previously 
described (TOYOBO) [33]. Real-time PCR was 
performed in duplicate using the Bio-Rad SYBR 
green super mix (Bio-Rad). The expression value 
was normalized to β-actin in the same sample. The 
sequences of the primer pairs are as follows: mIL-
17, forward, 5’-TCCAGAAGGCCCTCAGACTA-3’, 
reverse-AGCATCTTCTCGACCCTGAA; mRORγt: 
forward, 5’-GAAAGCAGGAGCAATGGAAG-3’, 
reverse 5’-CTCCACACCACCGTATTTGC -3’; mIL-21: 
forward 5’-TCCAGAAGGCCCTCAGACTA-3’, reverse 
5’-AGCATCTTCTCGACCCTGAA-3’; mβ-actin: forward 
5’-TGGAATCCTGTGGCATCCATGAAAC-3’, reverse 
5’-TAAAACGCAGCTCAGTAACAGTCCG-3’.
Flow cytometry
The isolation of PBMC was performed as previously 
described [34]. Staining markers were identified with 
relevant fluorochrome-conjugated anti-mouse-CD4, anti-
mouse-IL-17A, anti-human-CD3, anti-human-CD8, and 
anti-human-IL-17A mAb (eBioscience,) or Phospho-p38 
MAPK Rabbit mAb and anti-rabbit IgG (CST). 
Intracellular staining for Th17 cells or phospho-p38 
MAPK was performed as previously described [16]. The 
immunostained cells were analyzed using a FACS Calibur 
flow cytometer (BD Biosciences). 
ELISA
To detect IL-21 and IL-17A protein expression, 
ELISAs were performed with cytokine-specific kits from 
eBioscience according to the manufacturer’s instructions. 
Histological analysis
Murine joint tissue specimens were fixed in 
10% buffered formalin, followed by decalcification in 
15% formic acid overnight before being embedded in 
paraffin. Tissue sections (4 μm thick) were prepared for 
hematoxylin and eosin staining.
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Statistical analysis
Statistical significance was determined by a one-way 
analysis of variance or Student’s t-test. A Mann Whitney U 
test was used for the statistical analysis of human samples. 
Correlations between variables were determined by 
Spearman’s correlation coefficient. P values < 0.05 were 
considered significant. Data were analyzed with GraphPad 
Prism5 software and SPSS17.0 software.
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